Group items tagged

This Small Research Grant (R03) will support important and innovative projects focused on basic science approaches to elucidate neurodegenerative mechanisms/pathways of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Proposed projects should ultimately aim to improve the prevention, diagnosis, treatment, and/or care for individuals with AD/ADRD. The program seeks (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.

This notice announces the opportunity to apply for funding under the Ryan White HIV/AIDS (RWHAP) Program Part A Planning Council and Planning Body Technical Assistance (TA) Cooperative Agreement. The goal of this cooperative agreement is to provide comprehensive technical assistance to RWHAP Part A Planning Councils and Planning Bodies (Planning Councils/Bodies) to enable them to enhance their abilities to successfully meet legislative responsibilities. In an effort to meet goals and legislative responsibilities, the Health Resources and Services Administration (HRSA) will engage an organization with national reach to provide Planning Council- and transitional grant area (TGA) Planning Body-related technical assistance to recipients, jurisdictional leadership, and Planning Councils/Bodies support staff. Comprehensive site visits conducted by the HIV/AIDS Bureau (HAB) Division of Metropolitan HIV/AIDS Programs (DMHAP) for each of the 52 RWHAP Part A jurisdictions have identified a critical need for an ongoing, comprehensive technical assistance mechanism for Part A Planning Councils/Bodies. This technical assistance and support will enable them to enhance their abilities to successfully meet legislative requirements, strengthen their role in providing essential engagement of people with HIV, and increase the involvement of prevention and care and treatment providers in the RWHAP Part A planning process. The recipient of this cooperative agreement will offer a full range of technical assistance delivered through both in-person and virtual methods, including but not limited to creating and updating resource guidance tools.

The AANA Research Committee distributes grants for clinical or basic science research in the field of arthroscopic surgery or disorders amenable to arthroscopic treatment. The Education Foundation provides funding up to $100,000 in grant support. Fund amounts may vary depending on need and quality of work submitted.

Supported by the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH), EMF is inviting applications for its EMF/NIDA Mentor-Facilitated Training Award in Substance Use Disorders Science Dissemination. The award seeks works that addresses the overarching goals of EMF, including the promotion of knowledge of evidence-based SUD treatment among healthcare providers; the dissemination of substance use disorder research finding; the adoption of evidence-based approaches in medical settings, and the facilitation of the academic growth and development of future leaders in SUD management.

This Small Research Grant (R03) will support important and innovative projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this FOA will support archiving and leveraging existing data sets for analyses of projects covering a wide array of topics relating to AD/ADRD. The overall goal of this FOA is (i) to encourage the next generation of U.S. researchers to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support. Also listed under areas of research.

Encourages new investigators by providing seed and start-up funding for promising research projects that address issues related to the treatment of arthritis with an emphasis on arthroplasty. Clinical relevance must be clearly noted in the abstract and specific aims, and be obvious from the title and the study design. All proposed projects should generate results that have a practical application. It is expected that upon completion of the proposed project, the principal investigator will be well poised to pursue NIH/DOD or the equivalent large-scale funding to continue to advance the area of research.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

This notice announces the opportunity to apply for funding under the Ryan White HIV/AIDS Program (RWHAP) Implementation Program for HIV Clinical Quality Improvement. The purpose of this cooperative agreement is to provide RWHAP recipients and subrecipients with training and technical assistance (T/TA) to implement quality improvement methodologies (e.g., Model for Improvement, Lean, Lean Sigma), tools, and techniques, as required by the Ryan White HIV/AIDS Treatment Extension Act of 2009 and Clinical Quality Management Policy Clarification Notice 15-02 (CQM PCN 15-02). All T/TA will align with the CQM PCN 15-02. Although infrastructure and performance measurement are key components of CQM, this cooperative agreement will focus on quality improvement aimed at improving patient care, patient health outcomes, and patient satisfaction. The RWHAP Implementation Program for HIV Clinical Quality Improvement will provide T/TA to RWHAP recipients and subrecipients to identify and measure gaps in patient care, patient health outcomes, and patient satisfaction; implement quality improvement activities; and assess the impact of quality improvement activities. All T/TA should promote the adoption and implementation of quality improvement methodologies, tools, and techniques.This notice

The End TB Strategy envisions a world free of tuberculosis (TB)-zero deaths, disease and suffering due to TB by 2035. This requires reducing the global TB incidence from >1250 cases per million people to <100 cases per million people within the next two decades. Each year, an estimated 10 million people develop TB disease, and an estimated 1.6 million TB people die from TB - the leading cause of death from any infectious disease. In 2017, 90% of all estimated new TB cases were adults (15 years of age or older), and 9% were persons living with HIV (PLHIV) with 72% living in Africa. Despite being preventable and treatable, large gaps in detection and treatment of TB cases remain; of the estimated 10 million new TB cases in 2017, only 6.4 million TB cases were officially reported.

The FY19 GWIRP Clinical Evaluation Award supports translation of validated GWI research, including qualified and replicated preclinical findings, to a Gulf War Veteran population. The Clinical Evaluation Award targets the Verification phase of the research pipeline as outlined in Section II.A.2. Statistically powered biomarker trials with the potential to validate use of biomarkers as clinical endpoints or proof-of-concept intervention trials (e.g., pilot, first in human, Phase I-IIa) are encouraged under this funding opportunity. While studies of treatments repurposed from other disorders sharing GWI symptomatology will be considered (with appropriate rationale), the FY19 GWIRP encourages studies that translate qualified results from the GWI research community.

The opioid epidemic has disrupted public safety and significantly increased the burden on state and local law enforcement, substance abuse treatment delivery systems, mental health systems, child welfare and foster care, and the juvenile justice and criminal justice systems. Through this program, OJJDP is helping states and communities develop a data-driven, coordinated response to opioid abuse-related challenges that impact youth and community safety. Funding under this program may be used to support programs and services to youth and families impacted by both opioids and other substance use disorders.

The St. Baldrick's Foundation works hard to be sure that every dollar makes the biggest impact possible in childhood cancer research. The Foundation has held several Research Priorities Summits with many of the country's leading pediatric oncology researchers participating to advise the staff and board of directors on funding priorities. The St. Baldrick's team and Scientific Advisors meet regularly to be sure St. Baldrick's funds make the greatest impact on pediatric cancer research. Current funding priorities are divided into four categories: * New discovery research * Translational research and early phase clinical trials * Phase III clinical trials & infrastructure support of participating institutions (primarily the fall grant cycle) * Education of new pediatric oncology researchers In addition to research to understand the biology of childhood cancers and discover leads to more effective treatments, topics of interest include, but are not limited to: * Adolescents & young adults * Survivorship, outcomes, and quality of life * Supportive care * Epidemiology and pediatric cancer predispositions * Precision medicine * Alternative & complementary therapies

LIVESTRONG Cancer Institutes' mission: To rethink the full range of cancer care, from prevention to diagnosis, treatment, survivorship and end-of-life care - all with a focus on the patient's needs, values and preferences. Projects and organizations funded must also directly support the LIVESTRONG mission and the mission of the LIVESTRONG Cancer Institutes and should not be at odds with either mission.

Competitive applications will focus on studies that achieve one or more of the following goals: - Characterize disease progression for people with Parkinson's - Evaluate the utility of different instruments and/or instrument sub-items in measuring burden of disease, especially in individuals within the first two (2) years of Parkinson's diagnosis - Identify the role of pharmacological, medical device and/or non-medical interventions on managing Parkinson's symptoms and long-term health outcomes - Predict the future health status of participants without Parkinson's based on disease risk variables and model their likelihood of developing Parkinson's - Determine elements of disease experience that drive patient preference and risk tolerance - Explore the factors that affect volunteer compliance and completeness of participation in an online study - Determine how economic factors, patient-physician communication and lifestyle factors influence medical treatment and long-term health outcomes in people with Parkinson's - Analyst's choice: Researchers can submit their own analysis topics based on available Fox Insight data especially as it relates to longitudinal analyses

CMF works to improve health care outcomes through grant funding of: * Programs and initiatives that improve patient safety and quality of care through education and training of health care professionals or through systems changes and improvements; * Pilot programs that are designed to reduce medical errors; and * Development and implementation of checklists and other tools to improve disease management and transitions in care. The 2021 focus area is fragmentation across care settings. Breakdowns in care from a fragmented healthcare system can lead to readmissions, missed diagnoses, medication errors, delayed treatment, duplicative testing and procedures, and reduction in quality of care leading to general patient and provider dissatisfaction. Healthcare organizations must collaborate with each other and decide how to transfer information about patients they share. For example, health information technology can help providers share information about their patients. Organizations must devise strategies to "close the loop" and ensure that providers are aware of and address actionable patient information, such as test results.

The FirstRisk Advisors Initiatives in College Mental/Behavioral Health Funding Opportunity is designed to fund the development of creative initiatives that address prevention, early intervention, and treatment for mental and behavioral health disorders among students. The goal of these initiatives is to reduce the risk of mental and behavioral illness and injury among college students and to enhance both individual and community health as a strategy to support student learning. 

This FOA invites applications that apply a cross-disciplinary, team science approach to gain comprehensive, mechanistic understanding of the impact of sex differences on the trajectories of brain aging and phenotypes of AD risk and on the responsiveness to pharmacologic and non-pharmacologic interventions.  

The purpose of this Research Demonstration and Disseminations Projects (R18) Funding Opportunity Announcement (FOA) is to support research to evaluate large scale policies or programs related to healthcare delivery that are expected to influence diabetes prevention and care. This FOA is not intended to support the initiation and delivery of new policies or programs. Research support is for the evaluation of the effectiveness of healthcare programs and/or policies implemented independent of NIH grant funding. The goal is to support research that meaningfully informs clinical practice and health policy related to prevention or management of diabetes.

This Funding Opportunity Announcement (FOA) seeks to promote the development of HIV interventions which target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV.

The intent of the NETPR Program Career Progression Award is to support independent, early-career investigators who have innovative, high-impact ideas or new technologies applicable to PD research and/or patient care. This award provides an opportunity to obtain the funding and experience necessary for productive career progression at the forefront of research specifically on non-motor aspects of PD. Preliminary data to support the feasibility and rationale of the proposed work are required. Any preliminary data provided should be from the laboratory of the PI or collaborators.